Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, is pleased to announce that on June 29, 2017 its subsidiary, Guangzhou Concord Cancer Hospital Ltd., entered into an agreement with Varian Medical Systems Particle Therapy, GmbH, a subsidiary of Varian Medical Systems, Inc., for the purchase of a proton therapy system, and, on the same day, entered into an agreement with Varian Medical Systems Trading (Beijing) Co., Ltd. for the operation and maintenance of the proton therapy system.

Guangzhou Concord Cancer Hospital is Concord Medical's key high-end, "Level III" comprehensive cancer hospital project. Currently under construction, it is among Sino-Singapore Guangzhou Knowledge City's first batch of high-tech ancillary medical service projects. The hospital's phase I construction started in February 2017. The hospital will install multi-room ProBeam® proton therapy system manufactured by Varian with four 360° gantries.

Proton therapy, a form of radiation treatment that uses proton beam to target tumors with high precision, is well recognized as the most advanced form of radiation therapy available today. It has expanded its advantages in the clinical setting in terms of improving tumor control, significantly minimizing irradiation and damage for surrounding tissues and organs, and therefore reducing acute and late side effects as well as risks of secondary cancer, as well as shortening course of treatment with higher radiation doses per fraction. Nowadays, proton therapy is widely used in the treatment of various types of cancer.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "After the Guangzhou Concord Cancer Hospital is established, it will provide patients throughout China, especially for those in southern China, high-quality and humane radiation therapy services through the most advanced proton therapy equipment. In addition, through cooperation with the Sun Yat-Sen University Cancer Center, a well-known hospital in Guangzhou, in terms of the equipment, knowledge, treatment, management and medical experience, we aim to achieve interconnection, medical personnel exchange and scientific research sharing with the Sun Yat-Sen University Cancer Center. When the Guangzhou Concord Cancer Hospital is completed, it will be committed to passing the MD Anderson certification assessment and will aim to become one of the MD Anderson's cancer network associate members."

About Concord Medical

Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of June 30, 2016, the Company operated a network of 123 centers with 73 hospital partners that spanned 52 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. As part of its high-end cancer hospital development strategy and oversea business extension, the Company acquired Concord Cancer Hospital, a private hospital in Singapore in April, 2015.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.